Proteomic analysis identifies highly expressed plasma membrane proteins for detection and therapeutic targeting of specific breast cancer subtypes

Yvonne S. Ziegler, James J. Moresco, Patricia G. Tu, John R. Yates, Ann M. Nardulli

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

In recent years, there has been an emphasis on personalizing breast cancer treatment in order to avoid the debilitating side effects caused by broad-spectrum chemotherapeutic drug treatment. Development of personalized medicine requires the identification of proteins that are expressed by individual tumors. Herein, we reveal the identity of plasma membrane proteins that are overexpressed in estrogen receptor α-positive, HER2-positive, and triple negative breast cancer cells. The proteins we identified are involved in maintaining protein structure, intracellular homeostasis, and cellular architecture; enhancing cell proliferation and invasion; and influencing cell migration. These proteins may be useful for breast cancer detection and/or treatment.

Original languageEnglish (US)
Article number30
JournalClinical Proteomics
Volume15
Issue number1
DOIs
StatePublished - Sep 19 2018
Externally publishedYes

Fingerprint

Cell membranes
Proteomics
Blood Proteins
Membrane Proteins
Cell Membrane
Breast Neoplasms
Proteins
Triple Negative Breast Neoplasms
Drug therapy
Precision Medicine
Oncology
Cell proliferation
Therapeutics
Estrogen Receptors
Medicine
Cell Movement
Tumors
Homeostasis
Cells
Cell Proliferation

Keywords

  • Diagnostic markers
  • Estrogen receptor α-positive breast cancer
  • HER2-positive breast cancer
  • Individualized medicine
  • Plasma membrane proteins
  • Proteomic analysis
  • Triple negative breast cancer

ASJC Scopus subject areas

  • Molecular Medicine
  • Molecular Biology
  • Clinical Biochemistry

Cite this

Proteomic analysis identifies highly expressed plasma membrane proteins for detection and therapeutic targeting of specific breast cancer subtypes. / Ziegler, Yvonne S.; Moresco, James J.; Tu, Patricia G.; Yates, John R.; Nardulli, Ann M.

In: Clinical Proteomics, Vol. 15, No. 1, 30, 19.09.2018.

Research output: Contribution to journalArticle

@article{95716ce147b14ac3b6c74578fa95e5fc,
title = "Proteomic analysis identifies highly expressed plasma membrane proteins for detection and therapeutic targeting of specific breast cancer subtypes",
abstract = "In recent years, there has been an emphasis on personalizing breast cancer treatment in order to avoid the debilitating side effects caused by broad-spectrum chemotherapeutic drug treatment. Development of personalized medicine requires the identification of proteins that are expressed by individual tumors. Herein, we reveal the identity of plasma membrane proteins that are overexpressed in estrogen receptor α-positive, HER2-positive, and triple negative breast cancer cells. The proteins we identified are involved in maintaining protein structure, intracellular homeostasis, and cellular architecture; enhancing cell proliferation and invasion; and influencing cell migration. These proteins may be useful for breast cancer detection and/or treatment.",
keywords = "Diagnostic markers, Estrogen receptor α-positive breast cancer, HER2-positive breast cancer, Individualized medicine, Plasma membrane proteins, Proteomic analysis, Triple negative breast cancer",
author = "Ziegler, {Yvonne S.} and Moresco, {James J.} and Tu, {Patricia G.} and Yates, {John R.} and Nardulli, {Ann M.}",
year = "2018",
month = "9",
day = "19",
doi = "10.1186/s12014-018-9206-0",
language = "English (US)",
volume = "15",
journal = "Clinical Proteomics",
issn = "1542-6416",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - Proteomic analysis identifies highly expressed plasma membrane proteins for detection and therapeutic targeting of specific breast cancer subtypes

AU - Ziegler, Yvonne S.

AU - Moresco, James J.

AU - Tu, Patricia G.

AU - Yates, John R.

AU - Nardulli, Ann M.

PY - 2018/9/19

Y1 - 2018/9/19

N2 - In recent years, there has been an emphasis on personalizing breast cancer treatment in order to avoid the debilitating side effects caused by broad-spectrum chemotherapeutic drug treatment. Development of personalized medicine requires the identification of proteins that are expressed by individual tumors. Herein, we reveal the identity of plasma membrane proteins that are overexpressed in estrogen receptor α-positive, HER2-positive, and triple negative breast cancer cells. The proteins we identified are involved in maintaining protein structure, intracellular homeostasis, and cellular architecture; enhancing cell proliferation and invasion; and influencing cell migration. These proteins may be useful for breast cancer detection and/or treatment.

AB - In recent years, there has been an emphasis on personalizing breast cancer treatment in order to avoid the debilitating side effects caused by broad-spectrum chemotherapeutic drug treatment. Development of personalized medicine requires the identification of proteins that are expressed by individual tumors. Herein, we reveal the identity of plasma membrane proteins that are overexpressed in estrogen receptor α-positive, HER2-positive, and triple negative breast cancer cells. The proteins we identified are involved in maintaining protein structure, intracellular homeostasis, and cellular architecture; enhancing cell proliferation and invasion; and influencing cell migration. These proteins may be useful for breast cancer detection and/or treatment.

KW - Diagnostic markers

KW - Estrogen receptor α-positive breast cancer

KW - HER2-positive breast cancer

KW - Individualized medicine

KW - Plasma membrane proteins

KW - Proteomic analysis

KW - Triple negative breast cancer

UR - http://www.scopus.com/inward/record.url?scp=85053684182&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85053684182&partnerID=8YFLogxK

U2 - 10.1186/s12014-018-9206-0

DO - 10.1186/s12014-018-9206-0

M3 - Article

C2 - 30250408

AN - SCOPUS:85053684182

VL - 15

JO - Clinical Proteomics

JF - Clinical Proteomics

SN - 1542-6416

IS - 1

M1 - 30

ER -